Avalyn Pharma's IPO aims to fund inhaled IPF therapies as AP01 shows positive Phase II results. Read the full analysis here.
Boston-based biotech Avalyn Pharma is the latest to hop on the IPO train, filing to list on the Nasdaq and raise funds for ...
NTU Singapore is working with China's Southern University of Science and Technology (SUSTech) and Swedish biotechnology ...
University of Colorado Denver Biomedical Engineering Associate Professor Chelsea Magin is developing a lung model to help ...
The Pulmonary Fibrosis Foundation (PFF) today announced its PFF Walk 2026 schedule as the organization celebrates the 10 (th) season of the national fundraising program, which has raised more than $7.
Researchers at National Jewish Health and collaborating institutions have uncovered a critical mechanism driving persistent ...
A tiny antibody component could fundamentally transform the treatment of cystic fibrosis: For the first time, researchers ...
Backed by Novo Holdings and multiple other prominent investors, the biotech is developing what it’s positioning as superior ...
A tiny antibody component could fundamentally transform the treatment of cystic fibrosis: For the first time, researchers ...
A new inhaled therapy targets ANGPTL4 to reduce lung inflammation, fluid buildup, and scarring after infections. Preclinical ...
Pulmonary fibrosis is a progressive interstitial lung disease characterized by excessive extracellular matrix deposition, architectural distortion and declining lung function. While epithelial injury ...
Nanyang Technological University, Singapore (NTU Singapore) is working with China’s Southern University of Science and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results